title: Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.
abstract: We tested the hypothesis that levels of pentraxin high sensitivity C-reactive protein and pentraxin 3 might be correlated with cardiovascular complications in patients with essential thrombocythemia and polycythemia vera. High sensitivity C-reactive protein and pentraxin 3 were measured in 244 consecutive essential thrombocythemia and polycythemia vera patients in whom, after a median follow up of 5.3 years (range 0-24), 68 cardiovascular events were diagnosed. The highest C-reactive protein tertile was compared with the lowest (>3 vs. <1 mg/L) and correlated with age (P=0.001), phenotype (polycythemia vera vs. essential thrombocythemia, P=0.006), cardiovascular risk factors (P=0.012) and JAK2V617F allele burden greater than 50% (P=0.003). Major thrombosis rate was higher in the highest C-reactive protein tertile (P=0.01) and lower at the highest pentraxin 3 levels (P=0.045). These associations remained significant in multivariate analyses and indicate that blood levels of high sensitivity C-reactive protein and petraxin 3 independently and in opposite ways modulate the intrinsic risk of cardiovascular events in patients with myeloproliferative disorders.
authors.affiliation: Hematology Department, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy. tbarbui@ospedaliriuniti.bergamo.it
authors.forename: Tiziano
authors.initials: T
authors.lastname: Barbui
authors.forename: Alessandra
authors.initials: A
authors.lastname: Carobbio
authors.forename: Guido
authors.initials: G
authors.lastname: Finazzi
authors.forename: Alessandro M
authors.initials: AM
authors.lastname: Vannucchi
authors.forename: Giovanni
authors.initials: G
authors.lastname: Barosi
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Antonioli
authors.forename: Paola
authors.initials: P
authors.lastname: Guglielmelli
authors.forename: Alessandro
authors.initials: A
authors.lastname: Pancrazzi
authors.forename: Silvia
authors.initials: S
authors.lastname: Salmoiraghi
authors.forename: Pio
authors.initials: P
authors.lastname: Zilio
authors.forename: Cosimo
authors.initials: C
authors.lastname: Ottomano
authors.forename: Roberto
authors.initials: R
authors.lastname: Marchioli
authors.forename: Ivan
authors.initials: I
authors.lastname: Cuccovillo
authors.forename: Barbara
authors.initials: B
authors.lastname: Bottazzi
authors.forename: Alberto
authors.initials: A
authors.lastname: Mantovani
authors.forename: Alessandro
authors.initials: A
authors.lastname: Rambaldi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002097:C-Reactive Protein / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007249:Inflammation / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism; D053614:Janus Kinase 2 / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D011087:Polycythemia Vera / Q000097:blood / Q000150:complications* / Q000628:therapy; D011379:Prognosis; D012307:Risk Factors; D000683:Serum Amyloid P-Component / Q000378:metabolism*; D015996:Survival Rate; D013920:Thrombocythemia, Essential / Q000097:blood / Q000150:complications* / Q000628:therapy; D013927:Thrombosis / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism; D055815:Young Adult; D000099153:Pentraxins
chemical_list: D002097:C-Reactive Protein; D053614:Janus Kinase 2; D000683:Serum Amyloid P-Component; D000099153:Pentraxins; C507924:JAK2 protein, human